People
The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations Act in May 2019 has been sentenced.
The company, which has secured enormous investments over the past few years, is inching closer to being a commercial company in developing personalized therapies for a wide range of diseases, including cancer.
The two companies joined their consumer health businesses in order to give the parent companies more maneuverability to focus on the pharmaceuticals.
In a filing this week, the government said that tens of thousands of patients received “unreliable blood tests,” which deprived them of money and placed their health at risk.
The company’s chief executive officer, Ludwig Hantson, admits it’s a longshot.
In 2016, Soon-Shiong announced the Cancer Moonshot and set a 2020 deadline, claiming he would transform the war on cancer.
Candidates pointed out ways they would use the power of the federal government to lower the cost of medications in the United States.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No 596/2014.
Former Celgene and Wyeth leader with 30 years of global biopharmaceutical experience joins company as it prepares for first Biologics License Application (BLA) submission
Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces the appointments of Dr Alex Jackson as Head of Research and Development and of Archie Hale as Director of Clinical Operations.
PRESS RELEASES